Description
Clopidogrel-TEVA Coated Tablets 75 mg. №90
Ingredients
Each tablet contains 75 mg of Clopidogrel as the active ingredient.
Mechanism of Action
Clopidogrel exerts its pharmacological effects by irreversibly binding to the P2Y12 adenosine diphosphate receptor on platelets. This binding inhibits platelet activation and aggregation, thereby reducing the risk of thrombus formation.
Pharmacological Properties
Clopidogrel is a thienopyridine derivative antiplatelet agent that selectively inhibits platelet aggregation. It is a prodrug that requires metabolic activation in the liver to form its active metabolite, which then exerts its antiplatelet effects.
Indications for Use
Clopidogrel-TEVA is indicated for the prevention of atherothrombotic events in patients with a history of recent myocardial infarction, ischemic stroke, or peripheral arterial disease. It is also used in combination with aspirin for the prevention of stent thrombosis in patients undergoing percutaneous coronary intervention.
Contraindications
Clopidogrel-TEVA is contraindicated in individuals with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage. It should not be used in patients with hypersensitivity to clopidogrel or any component of the formulation.
Side Effects
The common side effects of Clopidogrel-TEVA include bleeding, bruising, gastrointestinal disturbances, and rash. Rare but serious side effects may include thrombotic thrombocytopenic purpura and neutropenia.
Usage Instructions
The recommended dosage of Clopidogrel-TEVA is one 75 mg tablet taken orally once daily, with or without food. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed.
Benefits Compared to Analogues
Clopidogrel has demonstrated superior efficacy over other antiplatelet agents, such as aspirin, in reducing the risk of cardiovascular events without significantly increasing the risk of major bleeding. Its once-daily dosing regimen offers convenience and improved patient adherence compared to other antiplatelet therapies.
Suitable Patient Groups
Clopidogrel-TEVA is suitable for adult patients, including the elderly, with atherosclerotic vascular disease who require antiplatelet therapy for secondary prevention of cardiovascular events. It is not recommended for use in children due to limited data on safety and efficacy in pediatric populations.
Storage and Shelf Life
Clopidogrel-TEVA tablets should be stored at room temperature (20-25°C) in a dry place away from direct sunlight and moisture. The shelf life of the product is typically 24 months from the date of manufacture.
Packaging Description
Clopidogrel-TEVA coated tablets are supplied in blister packs containing 90 tablets. The packaging is designed to protect the tablets from environmental factors and maintain their stability until the expiration date.
Scientific Evidence
Clinical studies have shown that Clopidogrel is effective in reducing the risk of major cardiovascular events, including myocardial infarction, stroke, and cardiovascular death. The landmark CAPRIE trial demonstrated a 8.7% risk reduction in the combined endpoint of ischemic stroke, myocardial infarction, or vascular death with clopidogrel compared to aspirin.
